Comparison · NCT04688775-a2ed3762
Eptinezumab vs Placebo: Number of Participants With ≥50% Reduction From Baseline in Number of Weekly Attacks in Week 1
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Eptinezumab vs Placebo: Number of Participants With ≥50% Reduction From Baseline in Number of Weekly Attacks in Week 1. Trial comparisons, record NCT04688775-a2ed3762. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04688775-a2ed3762
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.33 | 0.249 | 0.423 | wilson | |
| Risk in group 2 | 0.241 | 0.173 | 0.327 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0889 | -0.0289 | 0.204 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.37 | 0.9 | 2.08 | log | |
| Odds ratio, group 1 over group 2 | 1.55 | 0.865 | 2.78 | log | |
| Number needed to treat, for one more participant with the outcome on Eptinezumab than on Placebo | 11.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Eptinezumab | Participants received a single IV infusion of eptinezumab 400mg in 100 mL 0.9% saline solution. | 36 | 109 | OG000 |
| Group 2 | Placebo | Participants received a single IV infusion of 0.9% saline solution as matching placebo for eptinezumab. | 28 | 116 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With ≥50% Reduction From Baseline in Number of Weekly Attacks in Week 1
- Description
- Time frame
- Baseline (Week 0), Week 1
- Population
- The APRS included all randomized participants. Here, Overall Number of Participants Analyzed is the number of participants evaluable for this outcome measure.
Source ClinicalTrials.gov
Trial
- Title
- Eptinezumab in Participants With Episodic Cluster Headache
- NCT number
- NCT04688775
- Phases
- PHASE3
- Conditions
- Cluster Headache, Episodic
- Interventions
- Eptinezumab, Placebo
- Lead sponsor
- H. Lundbeck A/S
- Results first posted
- 2024-08-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04688775?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04688775-a2ed3762